SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome settled all SUNOSI patent litigation, granting five generic…

Axsome Therapeutics, Inc. · 8-K filed Jun 3, 2026 at 09:04 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 3, 2026 at 09:04 ET

Axsome settled all SUNOSI patent litigation, granting five generic companies entry rights no earlier than March 2040 (or September 2040 with pediatric exclusivity). This removes a major overhang and secures SUNOSI's exclusivity for over 14 years, significantly de-risking the product's long-term revenue stream.

  • All outstanding SUNOSI patent litigation resolved via settlement with the only remaining first-to-file generic applicant.
  • Five companies granted the right to sell generic SUNOSI beginning on or after September 1, 2040 (if pediatric exclusivity granted) or March 1, 2040 (if not), subject to FDA approval.
  • No other SUNOSI patent litigation remains pending.
  • Settlement will be submitted to FTC and DOJ for review.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access